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W6
THE APPROPRIATENESS OF COMMON MEDICAL 
DATA SOURCES: RANDOMIZED TRIALS, META-
ANALYSES, EPIDEMIOLOGICAL AND 
OBSERVATIONAL STUDIES FOR 
PHARMACOECONOMIC ANALYSES
Hasford J, Sangha O
Department of Medical Informatics, Biometry and 
Epidemiology, University of Munich, School of Medicine, 
Munich, Germany
The validity of pharmacoeconomic analyses relies on the
quality and appropriateness of the medical data sources
used. Randomized trials, meta-analyses, epidemiological
and observational studies will be presented and the pros
and cons discussed, with special emphasis on topics such
as internal and external validity, comparator treatments,
surrogate measures of outcome, assessment of adverse re-
actions, the place of diagnostics, and censored observa-
tions. Our own analyses, along with examples from the
literature, will be presented to describe the pitfalls en-
countered when using common medical data sources. We
aim firstly to sensitize the economist about shortcomings
when medical data are used for purposes they were not
originally collected for, and secondly to enable physicians
to critically assess pharmacoeconomic studies that are
based on empirical data.
W11
DECISION ANALYSIS IN CANCER THERAPY,
A NEW WAY FOR EVALUATION OUTCOMES 
WITH THE ANALYTIC HIERARCHY
PROCESS (AHP)
Reibnitz C, Silva, Saavedra M
School of Public Health, University of Bielefeld,
Bielefeld, Germany
The analytic hierarchy process (AHP) is a decision analysis
technique for evaluating complex multi-attributed alterna-
tives with conflicting objectives among one or more scores.
The AHP uses judgments from the decision maker and
hierarchical decomposition to derive a set of ratio-scaled
utility measures for decision alternatives. With the AHP,
there is no need to estimate a utility function explicitly,
because the AHP deals with stated preferences at each step.
The model may be used to give a stage 1 breast cancer pa-
tient the chance to discover the full extent and weight of
the decision for selecting breast cancer treatment, though
similar models could be built for any type of treatment
(e.g., cost-benefit analysis). The model allows for the opin-
ions of the physician and the legitimate concerns of the pa-
tient. Another problem inherent in the medical field is the
lag between new treatments and their long-term statistical
confirmation. For this reason, it is imperative that physi-
cian and patient alter relevant weights, given advance-
ments in medical knowledge, particular situational needs
and patient concerns. The issues of concern in the model
were identified as the total of psychological effects from
the treatment; expected length of time that the patient can
reasonably expect to live a normal life after a surgery deci-
sion is acted upon; the quality of preservation of the breast
tissue and surrounding structures; side effects which may
develop as a result of the surgery; and patient’s back-
ground, medical status, and cost. Though this model evalu-
ates general treatment options of surgical, non-surgical,
combination, or no treatment, specific alternatives of ther-
apies could also be analyzed.
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DEVELOPING INTERACTIVE COMPUTER 
SOFTWARE FOR EVALUATING THE ECONOMIC 
AND CLINICAL OUTCOMES OF VARIOUS 
TREATMENT STRATEGIES
McGhan WF
University of the Sciences at Philadelphia. Philadelphia, PA, US
The objective of this workshop is to demonstrate how in-
teractive software programs are useful tools in healthcare
decision-making as well as educational tools on specific
diseases and the decision-making process. In this work-
shop, a specific disease, gastroesophageal reflux disease
(GERD), will be used as the example. Decision support
systems are tools that allow systematic approaches to deci-
sion-making under conditions of uncertainty. There are
four steps in decision system development: 1) to identify
and bound the decision problem, 2) to structure the deci-
sion problem over time, 3) to characterize the information
needed to structure the decision, and 4) to perform the
analysis to reveal the preferred course of action. In this
workshop, a decision tree analysis will be demonstrated.
The branches of the tree describing the clinical pathway
treatment options will be discussed. The decision nodes
(treatment options), probability nodes (healing rates), and
resulting outcomes will be demonstrated. Sensitivity analy-
sis (changing one variable, such as one of the costs, or
changing two or three variables at one time) will be dem-
onstrated. Interactive software programs have the addi-
tional benefit as educational tools to self-instruct on the
clinical issues of a specific disease. Attendees will see how
the use of photos, graphics, and dictionaries within the de-
cision support software program can enhance the value of
the program as a user-friendly educational tool.
TRACK 2: GUIDELINES AND STANDARDS
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Langley P
Program in Pharmaceutical Economics and Health Systems 
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Managed care groups, physician management organiza-
tions, and independent practice associations in the United
States are increasingly seeing formulary submission
guidelines as a key management tool for cost and quality
control within health systems. The purpose of this work-
shop is to describe the process of guideline development,
the analytical and evaluative standards required from
those making submissions and the implementation of
guidelines within managed care health systems. The focus
is on the guidelines recently put in place by Blue Cross
Blue Shield of Colorado, Nevada, and New Mexico (with
over 0.5 million members), which were developed at the
University of Colorado, and similar guidelines in the pro-
cess of development for the Academy of Managed Care
Pharmacy in Washington, DC. Of particular importance
in this presentation are the analytical and evaluative stan-
dards required in the guidelines. While the guidelines are
similar in a number of respects to the revised November
1995 Australian guidelines, the central requirement is for
projections to be made of the net cost and outcomes im-
pact on a treating population from the introduction of a
new drug or therapy intervention in disease or treatment
areas. This is described as a systems impact assessment,
which is quite different from the analytical focus of tradi-
tional pharmaceutical economics. Rather than base for-
mulary decisions on implications drawn from synthetic
decision models, the guidelines ask for cost and outcome
impact assessments which are, in principle, verifiable.
This means they can serve as a basis for monitoring
health impact assessments of set targets and in the con-
text of disease or care management interventions.
W10
PRO AND CON: USE OF DATA FROM FOREIGN 
PHARMACOECONOMIC INVESTIGATIONS
IN RUSSIA
Stratchounski L, Rozenson O
Smolensk State Medical Academy, Smolensk, Russia
Pharmacoeconomic data are extremely useful for the de-
velopment of optimal treatment strategies in terms of clini-
cal efficacy, safety, and cost of drug therapy. Although sev-
eral pharmacoeconomic trials have been conducted in
Russia, these data are quite scarce in our country. In the
majority of cases, foreign data are the only available sources
of information. The main advantages of these data are
their methodology, design, and modern approaches to data
analyses and interpretation. However, Russian doctors
and health authorities should be very careful in using data
obtained abroad. As far as we are concerned, there are at
least four principal limitations for these data in Russia.
Firstly, variations in epidemiology of given diseases exist
among different countries. Secondly, we see a difference in
drug prices; for instance, cefotaxime (1 g) costs 2.44 USD
in Russia versus 11.7 USD in the US. Thirdly, the costs of
medical service and hospitalization are much less costly in
Russia than in Western countries—the cost per ICU day in
Russia is about 100 USD (Smolensk Regional Hospital),
whereas in the US it is about 1000 USD (Millard Fillmore
Suburban Hospital, Williamsville, NY). This may explain
to some extent the lack of sufficient attention paid by Rus-
sian physicians to the duration of hospitalization. The total
cost of treatment nowadays in Russia predominantly de-
pends on drug therapy cost. Finally, there are differences in
financing sources of health services between countries. The
Russian healthcare system is predominantly funded by the
Government and/or insurance companies. Moreover, there
are often different sources of financing within one region.
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STANDARDIZATION IN THE PUBLIC HEALTH 
SYSTEM OF RUSSIA: THE FIRST EXPERIENCE
Vorobyev PA1, Aksyuk AV1, Yakimov OS1, Novolodsky VM1, 
Kuzin VF1, Kobina SA2
1Moscow Medical Academy, Laboratory of Outcomes and 
Standardization Research, Moscow, Russia; 2Rhône-Poulenc 
Moscow Representative Office, Pharmacoeconomics 
Department, Moscow, Russia
Since 1998, the standardization system in Russia has been
functioning in the public health system, which corresponds
with the state system of standardization and with the inter-
national requirements in this field. This system is to solve
the following major problems: 1) to assure that citizens
shall exercise their rights to generally available free of
charge medical care of high quality; 2) to provide the com-
pulsory health insurance system in Russia with a standard-
izing base; and 3) to provide the certification and quality
assessment system to be set up in the health public system
with standards and specifications. At the first stage of de-
velopment, 16 groups of standardization objects were iden-
tified and the basic principles formulated. The most impor-
tant principles are a consensuality principle (i.e., a mutual
agreement between all the parties engaged in the develop-
ment and use of standards), an actuality principle (i.e.,
compliance of the elaborated documents with legislative
and other international and state requirements), and a com-
plexity principle (i.e., solution of problems of standard-
ization in all spheres of citizen healthcare by uniform
methods). At the second stage, a working program on the
establishment and development of a public health stan-
dardization system in Russia was worked out and ap-
proved, highlighting the priorities of work, defining a list of
priority regulatory documents, and executing this work.
Particular emphasis is placed on a group of system-forming
documents: a group of documents that regulate the terms,
conditions, and quality of the medical services rendered;
and a group of documents pertaining to drug provision,
medical equipment, informational technologies, etc. Assim-
ilation of the results of new studies in pharmacological
economy and evidence-based medicine will be a very im-
portant element of development of the documents regulat-
ing the rendering of medical services. The specialists of the
pharmaceutical company Rhône-Poulenc, whose collabora-
tion helps to introduce mathematical programs and infor-
mational technologies into the development of a program
